title: Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?
abstract: Liposomal amphotericin B has been used as an alternative treatment of mucosal leishmaniasis, but the optimal dose is not established. We retrospectively reviewed the clinical outcome of eight patients with mucosal leishmaniasis treated with liposomal amphotericin B. The mean total dose was 35 mg/kg (range 24-50 mg/kg), which resulted in the healing of all the lesions in all patients and no recurrences were observed during the follow-up period (mean 25 months; range 7-40 months).
authors: Division of Infectious and Parasitic Diseases, Hospital das Clínicas, University of São Paulo, Medical School, Brazil. valdirsa@netpoint.com.br
authors: Valdir S
authors: VS
authors: Amato
authors: Felipe F
authors: FF
authors: Tuon
authors: Raphael A
authors: RA
authors: Camargo
authors: Regina M
authors: RM
authors: Souza
authors: Carolina R
authors: CR
authors: Santos
authors: Antonio C
authors: AC
authors: Nicodemo
mesh_terms: D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: C068538:liposomal amphotericin B; D000666:Amphotericin B